<p>[단독/외신] 온코섹 표적항암제 TAVO 흑색종암 임상3상 뛰어난효능입증 <br>#알파홀딩스(117670) <br><br>. TAVO™-EP에 대한 최근 수행된 임상 연구의 결과는 국소적인 항바이러스 면역 반응을 보여주었고, 이후 수용 가능한 안전 프로필과 함께 단일 요법 또는 조합 치료 접근법으로서의 체계적인 치료 효과를 입증하였다  <br><a href="https://ir.oncosec.com/press-releases/detail/2104/oncosec-to-present-at-the-rhk-capital-disruptive-growth" target="_blank" class="ke-link">https://ir.oncosec.com/press-releases/detail/2104/oncosec-to-present-at-the-rhk-capital-disruptive-growth</a><br><br><br></p><div class="figure-open" contenteditable="false" data-ke-type="opengraph" data-ke-align="alignCenter" data-og-type="website" data-og-title="OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022" data-og-description="PENNINGTON, N.J. and SAN DIEGO, Dec. 5, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient's own " data-og-host="ir.oncosec.com" data-og-source-url="https://ir.oncosec.com/press-releases/detail/2104/oncosec-to-present-at-the-rhk-capital-disruptive-growth" data-og-url="https://ir.oncosec.com/press-releases/detail/2104/oncosec-to-present-at-the-rhk-capital-disruptive-growth" data-og-image="https://scrap.kakaocdn.net/dn/m8d6f/hyQPaYbYLX/LCDbCdiuF9Jrt9rK3zuSyk/img.jpg?width=1200&height=627&face=0_0_1200_627"><a href="https://ir.oncosec.com/press-releases/detail/2104/oncosec-to-present-at-the-rhk-capital-disruptive-growth" target="_blank" data-source-url="https://ir.oncosec.com/press-releases/detail/2104/oncosec-to-present-at-the-rhk-capital-disruptive-growth"><div class="og-image" style="background-image:url(https://scrap.kakaocdn.net/dn/m8d6f/hyQPaYbYLX/LCDbCdiuF9Jrt9rK3zuSyk/img.jpg?width=1200&height=627&face=0_0_1200_627)"></div><div class="og-text"><p class="og-title">OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022</p><p class="og-desc">PENNINGTON, N.J. and SAN DIEGO, Dec. 5, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient's own </p><p class="og-host">ir.oncosec.com</p></div></a></div><p> </p><p><span data-ke-size="size14">*** 본 정보는 투자 참고용 자료로서 그 정확성이나 완전성을 보장할 수 없으며, 어떠한 경우에도 법적 책임소재에 대한 증빙자료로 사용될 수 없습니다.</span></p><div class="table-wrap"><table data-ke-type="table" data-ke-align="alignLeft" style="width: 100%; height: 75px;" border="1" data-ke-style="style13"><tbody><tr style="height: 75px;"><td style="width: 756px; height: 75px; text-align: center;"><a href="https://cafe.daum.net/stockwang/As9F/3070" target="_blank" class="ke-link"><span style="color: #ee2323;" data-ke-size="size26"><b>'돈' 잃지 마라! '돈'을 지켜라! 그리고 '돈'을 불려라!</b></span></a></td></tr></tbody></table></div><p> </p>
<!-- -->
